Carlisle is in a broad, range-bound consolidation with a distinctly negative longer-term tilt: the shares are down 14.49% over the past year versus a 16.22% gain for SPY, a relative-strength gap of -30.71 percentage points that marks sustained underperformance. At $335.24, the stock sits at roughly 30.0% of its 52-week range of $293.43–$432.91, meaning it is trading in the lower third of its annual band — closer to value-territory than momentum-territory, and well below the highs that would signal trend strength. The 25.96% maximum drawdown confirms this has been a distribution/derating phase rather than a healthy pullback within an uptrend, and the burden of proof now sits with buyers to defend the low end of the range.\n\nShort-term momentum has deteriorated sharply even as the stock bounced 1.67% on the latest session: the 1-month change is -12.38% versus a 3-month change of -2.48% and a 6-month change of -1.80%, a clear deceleration pattern in which the most recent month accounts for the bulk of the recent weakness. That -12.38% one-month move badly lags SPY's -1.06% over the same window, producing a -11.32 percentage-point relative-strength deficit that suggests company-specific selling pressure (likely tied to deal uncertainty and soft order trends) rather than mere market beta. Notably, the year-to-date change is still positive at +2.06%, so the recent slide has erased most but not all of 2026's gains — a divergence that argues for caution until the 1-month trend stabilizes. Volume of roughly 416,000 shares on the latest print is modest, offering little evidence of capitulation or of institutional accumulation.\n\nTechnically, the $293.43 52-week low is the critical support zone, with the recent $322–$330 area acting as a nearer-term shelf; a decisive break below $293 would confirm a new leg lower and likely invite momentum-driven selling. To the upside, $432.91 marks the 52-week high and the level that must be reclaimed to invalidate the downtrend, with intermediate resistance around $360–$390 where the stock repeatedly failed in July and August. The beta of 0.835 is a meaningful offset for risk management: Carlisle is roughly 16.5% less volatile than the market, so position sizing can be somewhat larger for the same dollar risk, but low beta also means the stock will not lead a broad market rally — it needs idiosyncratic catalysts (deal resolution, roofing price/mix improvement) to re-rate.\n\n

Carlisle's top line is decelerating: Q1 2026 revenue was $1.052 billion, down 3.99% year over year from $1.096 billion in Q1 2025, extending a pattern of sequential decline from $1.450 billion in Q2 2025 and $1.347 billion in Q3 2025 to $1.128 billion in Q4 2025. The revenue mix is heavily concentrated — CCM generated $758.1 million and CWT $294.0 million in the most recent segment disclosure — so the consolidated trajectory is effectively a CCM story, and the year-over-year contraction points to softer commercial roofing volumes and/or less favorable price/mix rather than a broad-based collapse. For the investment case, this means the growth algorithm has shifted from volume-driven expansion to cost control, price discipline, and capital deployment; consensus revenue of roughly $6.25 billion for the forward period implies only modest sequential recovery, so multiple expansion from here likely requires either a demand inflection or the Owens Corning transaction to close on accretive terms.\n\nProfitability remains solid but is compressing at the margin: Q1 2026 net income was $127.7 million on a 12.14% net margin, with gross margin of 34.52% versus 35.20% in Q1 2025 and 37.33% in Q2 2025 — a clear downward drift in gross profitability over the past four quarters. Operating income of $180.3 million (17.14% operating margin) and EBITDA of $240.7 million (22.88% EBITDA margin) are healthy in absolute terms and compare favorably with typical building-products peers, but the trend matters more than the level: gross margin has fallen roughly 280 basis points from the Q2 2025 peak, and net income of $127.7 million is down from $143.3 million a year earlier despite a lower share count. The company remains comfortably profitable with a 14.76% trailing net margin and 19.92% operating margin, but the direction of travel suggests input costs, mix, and volume deleverage are eroding the pricing power that historically justified Carlisle's premium multiple.\n\nThe balance sheet is the key swing factor: debt-to-equity stands at 1.60x, the current ratio is a healthy 3.09, and trailing free cash flow is $924.8 million, but the most recent quarter showed negative operating cash flow of -$44.7 million and negative free cash flow of -$73.0 million driven by a $241.8 million working-capital build and $250 million of buybacks. Cash on hand fell to $771.3 million from $1.112 billion at year-end 2025, and with $45.7 million of dividends paid and $28.3 million of capex in the quarter, the company is currently funding shareholder returns partly from the balance sheet rather than from internal cash generation. ROE of 41.26% and ROA of 10.81% are impressive but flattered by leverage and buyback-reduced equity; the 1.60x debt-to-equity ratio and the prospect of a large debt-funded acquisition mean financial flexibility — not growth — is the constraint investors should monitor most closely.\n\n